EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug‐resistant focal seizures

Mar Carreño iD, Antonio Gil-Nagel iD, José M Serratosa, Manuel Toledo, Juan Jesus Rodriguez-Uranga iD, Vicente Villanueva iD

Epilepsia Open · 2024

DOI: 10.1002/epi4.12936 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2024. Verfasst von Mar Carreño und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Clinic Barcelona, Epilepsy Unit, Barcelona, Spain. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Drug Resistant Epilepsy, Drug Therapy, Combination. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cenobamate is an antiseizure medication (ASM) associated with high rates of seizure freedom and acceptable tolerability in patients with focal seizures. To achieve the optimal cenobamate dose for maximal potential effectiveness while avoiding or minimizing drug‐related adverse events (AEs), the administration of cenobamate with other ASMs must be managed through concomitant ASM load reduction. A panel of Spanish epilepsy experts aimed to provide a Spanish consensus on how to adjust the dose of concomitant ASMs in patients with drug‐resistant epilepsy (DRE) in order to improve the effectiveness and tolerability of adjunctive cenobamate.

Methods

A three‐stage modified Delphi consensus process was undertaken, including six Spanish epileptologists with extensive experience using cenobamate. Based on current literature and their own expert opinion, the expert panel reached a consensus on when and how to adjust the dosage of concomitant ASMs during cenobamate titration.

Results

The expert panel agreed that tailored titration and close follow‐up are required to achieve the best efficacy and tolerability when initiating cenobamate in patients receiving concomitant ASMs. When concomitant clobazam, phenytoin, phenobarbital, and sodium channel blockers are taken at high dosages, or when the patient is receiving two or more sodium channel blockers, dosages should be proactively lowered during the cenobamate titration period. Other concomitant ASMs should be reduced only if the patient reports a moderate/severe AE at any stage of the titration period. Significance Cenobamate is an effective ASM with a dose‐dependent effect. To maximize effectiveness while maintaining the best tolerability profile, co‐medication management is needed. The recommendations included herein provide practical guidance for proactive and reactive management of co‐medication in cenobamate‐treated patients with DRE and a high drug load. Plain Language Summary Patients with epilepsy may continue to have seizures even after treatment with several different antiseizure medications (ASMs). Cenobamate is an ASM that can reduce seizures in these patients. In this study, six Spanish experts in epilepsy discussed the best way to use cenobamate in drug‐resistant epilepsy. They provide practical guidance on when and how the dose of other ASMs might be adjusted to reduce side effects and optimize the use of cenobamate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsCarbamatesDrug Resistant EpilepsyDrug Therapy, CombinationChlorophenolsHumansSpainAdultEpilepsies, PartialSeizuresDelphi TechniqueTetrazoles

Stichwörter der Autor:innen

antiseizure medicationcenobamatedosage adjustmentepilepsytitration

Substanzen

AnticonvulsantsCarbamatesCenobamateChlorophenolsTetrazoles

Autor:innen und Institutionen

  • Hospital Clinic Barcelona, Epilepsy Unit, Barcelona, Spain.
  • Department of Neurology, Epilepsy Program, Ruber International Hospital, Madrid, Spain.
  • Department of Neurology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Vall d'Hebron University Hospital, Epilepsy Unit, Barcelona, Spain.
  • Advanced Neurological Centre, Seville, Spain.
  • La Fe University and Polytechnic Hospital, Refractory Epilepsy Unit, Valencia, Spain.

ORCID-Profile: Mar Carreño, Antonio Gil-Nagel, Juan Jesus Rodriguez-Uranga, Vicente Villanueva

Zitieren

APA

Carreño, M., Gil-Nagel, A., Serratosa, J. M., Toledo, M., Rodriguez-Uranga, J. J., & Villanueva, V. (2024). Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug‐resistant focal seizures. Epilepsia Open. https://doi.org/10.1002/epi4.12936

Vancouver

Carreño M, Gil-Nagel A, Serratosa JM, Toledo M, Rodriguez-Uranga JJ, Villanueva V. Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug‐resistant focal seizures. Epilepsia Open. 2024. doi:10.1002/epi4.12936

BibTeX
@article{Carreo2024,
  author = {Carreño, Mar and Gil-Nagel, Antonio and Serratosa, José M and Toledo, Manuel and Rodriguez-Uranga, Juan Jesus and Villanueva, Vicente},
  title = {Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug‐resistant focal seizures},
  journal = {Epilepsia Open},
  year = {2024},
  doi = {10.1002/epi4.12936}
}
Kostenlos starten →